Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.

ABSTRACT:

Background

Parkinson disease (PD) psychosis (PDP) is a disabling non-motor symptom. Pharmacologic treatment is limited to pimavanserin, quetiapine, and clozapine, which do not worsen parkinsonism. A Food and Drug Administration black box warning exists for antipsychotics, suggesting increased mortality in elderly patients with dementia. However, the reasons for higher mortality are unknown.

Aim

Expanding on prior work exploring mortality in treated PDP patients, we conducted a retrospective comparison to understand the links between treatment regimen, clinical characteristics, and negative outcomes.

Methods

Electronic medical record data extraction included clinically diagnosed PD patients between 4/29/16-4/29/19 and excluded patients with primary psychiatric diagnose

SUBMITTER: Longardner K 

PROVIDER: S-EPMC9882782 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature